福泰制药

Vertex Pharmaceuticals: MACD Death Cross and Bollinger Bands Expanding Downward on 15min chart.

Vertex Pharmaceuticals

Bernstein Upgrades Vertex Pharmaceuticals to Outperform, Predicting an 8.01% Upside

Bernstein upgrades Vertex Pharmaceuticals to Outperform from Market Perform rating.

Medline

Bernstein Initiates Outperform Rating on Vertex Pharmaceuticals with $49 PT

Vertex Pharmaceuticals Reports Business and Program Updates Ahead of Investor Meetings in January 2026

Catalyst<ul> <li>Most analysts rate VRTX Buy or Strong Buy, showing broad institutional optimism.</li> <li>Small and medium fund flows are positive, indicating inflows from smaller and mid-sized investors.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Market expectations tend to be pessimistic according to analyst ratings.</li> <li>Large and extra-large fund flows are negative, indicating outflows from major investors.</li> <li>Gross profit margin is a negative fundamental factor for VRTX.</li></ul>

Key Factors

Vertex Pharmaceuticals will release its fourth-quarter 2025 financial results and full-year 2026 guidance before the market opens on February 11, 2026.Bernstein upgraded Vertex Pharmaceuticals to Outperform from Market Perform, with an average one-year price target of $501.03 per share.Vertex Pharmaceuticals announced business and program updates, including progress in its cystic fibrosis pipeline and expansion of its commercial and renal franchises ahead of investor meetings in January 2026.

Recent Updates

VRTX News